Darbepoetin Alfa

證據等級: L5

預測適應症: 0 個

Darbepoetin Alfa: Evaluation Pending — No Active TxGNN Repurposing Prediction

One-Sentence Summary

Darbepoetin alfa is a hyperglycosylated erythropoiesis-stimulating agent (ESA) indicated internationally for the treatment of anaemia in chronic kidney disease and chemotherapy-induced anaemia. The TxGNN model did not generate any repurposing prediction for this candidate in the current run. Two blocking or high-severity data gaps — missing regulatory warning data and missing mechanism of action data — prevent formal evaluation and must be resolved before the pipeline can be re-executed.

Quick Overview

Item	Content
Original Indication	Anaemia (chronic kidney disease; chemotherapy-induced) — based on international sources; not populated in evidence pack
Predicted New Indication	— (no prediction generated)
TxGNN Prediction Score	—
Evidence Level	Not evaluable (pipeline returned no candidates)
Denmark Market Status	Not marketed (per evidence pack)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why No Prediction Was Generated

The TxGNN pipeline returned an empty predicted_indications list for darbepoetin alfa (DrugBank: DB00012). Based on the evidence pack metadata and data gap log, the most likely causes are:

1. Missing mechanism of action (DG002 — High severity) TxGNN’s graph neural network reasoning relies on drug–protein–disease edges in the knowledge graph. Without MOA annotation — specifically the drug’s target proteins and pharmacological class — the drug node is likely insufficiently connected to score candidate disease associations. Darbepoetin alfa acts via the erythropoietin receptor (EPOR) and downstream JAK2/STAT5 signalling; this information is well-documented in DrugBank but was not retrieved in the current run.

2. Empty original indications array The original_indications field is unpopulated. The prediction pipeline may depend on existing indication anchors to seed the disease neighbourhood search. Without them, candidate scoring may have been skipped or returned below the reporting threshold.

3. Blocking data gap (DG001 — Blocking severity) Local regulatory warning and contraindication data is absent. While this does not directly affect the prediction algorithm, it prevents any downstream safety screening of hypothetical candidates, making the entire evaluation incomplete even if predictions were available.

Darbepoetin alfa is an established biologic with a long safety and efficacy record. Repurposing hypotheses explored in the literature include neuroprotection (ischaemic stroke, traumatic brain injury), cardioprotection (acute myocardial infarction), and anti-inflammatory applications — all driven by EPOR expression outside erythroid tissue. None of these appear in this evidence pack.

Denmark Market Information

The evidence pack records zero marketing authorisations for darbepoetin alfa and a market status of “not marketed.”

⚠️ Data Consistency Alert: This appears inconsistent with publicly available information. Aranesp® (darbepoetin alfa, Amgen Europe B.V.) holds a centralised EMA marketing authorisation (EU/1/01/183/001–020) valid across all EU/EEA Member States, including Denmark, since 2001. Investigators should verify the current authorisation status directly with:

EMA EPAR for Aranesp

The Danish Medicines Agency product database (laegemiddelstyrelsen.dk)

The evidence pack candidate ID carries a TW- prefix, suggesting the regulatory data was sourced from a Taiwan-market dataset rather than the Danish/EMA register. This must be corrected before Denmark-specific conclusions are drawn.

Safety Considerations

All safety fields in the evidence pack are recorded as data gaps. No warnings, contraindications, or drug–drug interaction data are available for evaluation within this pack.

Please refer to the approved Summary of Product Characteristics (SmPC) for all darbepoetin alfa-containing products for full safety information.

Key safety areas that should be reviewed in the SmPC prior to any repurposing evaluation include:

Cardiovascular risk: Thromboembolic events and increased mortality have been reported when ESAs were used to target haemoglobin levels above the approved range
Tumour progression: EPOR is expressed on some tumour cell lines; ESA use in oncology settings requires careful benefit–risk assessment
Pure red cell aplasia (PRCA): Rare but serious immunogenicity-related adverse event; neutralising anti-erythropoietin antibodies
Hypertension: New-onset or worsening hypertension is a known class effect

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline returned no repurposing candidates for this drug, and two unresolved data gaps — one blocking and one high-severity — prevent any meaningful safety or mechanistic evaluation. No report section can be completed based solely on the current evidence pack.

To proceed, the following is needed:

Resolve DG001 (Blocking) — Retrieve and parse the applicable SmPC (EMA SmPC for Aranesp® recommended) to extract warnings, contraindications, and special populations data
Resolve DG002 (High) — Query the DrugBank API (DB00012) for mechanism of action, primary targets (EPOR, JAK2), and pharmacological class
Correct the regulatory data source — Replace the TW- Taiwan regulatory data with data sourced from the EMA/Laegemiddelstyrelsen register; populate total_licenses and licenses accordingly
Populate original_indications — Add the internationally recognised indications so the prediction pipeline can use them as graph anchors
Re-run the TxGNN prediction pipeline — Once MOA and indication data are populated, re-execute both the KG and DL prediction steps to generate ranked candidate indications
Re-evaluate — A full L1–L5 evidence assessment, clinical trial table, and literature review can only be completed once at least one prediction candidate is returned

This report was generated on 2026-04-05. Results are for research purposes only and do not constitute medical advice. Any repurposing candidate must undergo clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.